PB 83 of 2024
National Health (Minimum Stockholding) Amendment Determination (No. 7) 2024
I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.
Dated 30 July 2024
Nikolai Tsyganov
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care
Contents
1 Name
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments commencing 1 August 2024
National Health (Minimum Stockholding) Determination 2023
(1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 7) 2024.
(2) This instrument may also be cited as PB 83 of 2024.
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 August 2024. | 1 August 2024 |
2. Schedule 1 | 1 August 2024. | 1 August 2024 |
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments commencing 1 August 2024
National Health (Minimum Stockholding) Determination 2023
1 Schedule 1 (table)
Before:
Acamprosate | Tablet (enteric coated) containing acamprosate calcium 333 mg | Oral | Acamprosate Viatris | after 30 July 2024—4 months stock by reference to usual demand of both Acamprosate Viatris and Acamprosate Mylan added together. |
insert:
Abacavir with lamivudine | Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg | Oral | ABACAVIR/LAMIVUDINE 600/300 SUN | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
2 Schedule 1 (table)
After:
Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | ENTRIP | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand |
insert:
Amlodipine | Tablet 10 mg (as besilate) | Oral | BTC Amlodipine | between 1 August 2024 and 31 August 2024—0 months stock by reference to usual demand |
Amlodipine | Tablet 5 mg (as besilate) | Oral | BTC Amlodipine | between 1 August 2024 and 31 August 2024—0 months stock by reference to usual demand |
Amoxicillin | Capsule 500 mg (as trihydrate) | Oral | NOUMED AMOXICILLIN | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
3 Schedule 1 (table)
After:
Aripiprazole | Tablet 10 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
insert:
Aripiprazole | Tablet 10 mg | Oral | Tevaripiprazole | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
4 Schedule 1 (table)
After:
Aripiprazole | Tablet 15 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
insert:
Aripiprazole | Tablet 15 mg | Oral | Tevaripiprazole | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
5 Schedule 1 (table)
After:
Aripiprazole | Tablet 20 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
insert:
Aripiprazole | Tablet 20 mg | Oral | Tevaripiprazole | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
6 Schedule 1 (table)
After:
Aripiprazole | Tablet 30 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
insert:
Aripiprazole | Tablet 30 mg | Oral | Tevaripiprazole | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
7 Schedule 1 (table)
After:
Atorvastatin | Tablet 40 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
insert:
Atorvastatin | Tablet 80 mg (as calcium) | Oral | Atorvastatin GH | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
8 Schedule 1 (table)
After:
Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL | Oral | Zithromax | 4 months stock by reference to usual PBS demand |
insert:
Azithromycin | Tablet 500 mg (as dihydrate) | Oral | Azithromycin Viatris | after 30 September 2024—4 months stock by reference to usual demand of both Azithromycin Viatris and Azithromycin Mylan added together |
9 Schedule 1 (table)
Omit:
Bosentan | Tablet 125 mg (as monohydrate) | Oral | Bosentan Cipla | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |
10 Schedule 1 (table)
Omit:
Cefazolin | Powder for injection 500 mg (as sodium) | Injection | Cefazolin-AFT | between 1 May 2024 and 30 July 2024—0 months stock by reference to usual demand |
11 Schedule 1 (table)
After:
Ciclosporin | Oral liquid 100 mg per mL, 50 mL | Oral | Neoral | 4 months stock by reference to usual PBS demand |
insert:
Ciprofloxacin | Tablet 500 mg (as hydrochloride) | Oral | Cifran | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
12 Schedule 1 (table)
After:
Codeine | Tablet containing codeine phosphate hemihydrate 30 mg | Oral | Aspen Pharma Pty Ltd | 4 months stock by reference to usual PBS demand |
insert:
Cyproterone | Tablet containing cyproterone acetate 100 mg | Oral | Pharmacor Cyproterone 100 | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | Pharmacor Cyproterone 50 | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
13 Schedule 1 (table)
After:
Dolutegravir with abacavir and lamivudine | Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg | Oral | Triumeq | 6 months stock by reference to usual PBS demand |
insert:
Donepezil | Tablet containing donepezil hydrochloride 10 mg | Oral | NOUMED DONEPEZIL | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
Donepezil | Tablet containing donepezil hydrochloride 5 mg | Oral | NOUMED DONEPEZIL | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
14 Schedule 1 (table)
After:
Enalapril | Tablet containing enalapril maleate 20 mg | Oral | APO‑Enalapril | 3 months stock by reference to usual demand |
insert:
Enalapril | Tablet containing enalapril maleate 20 mg | Oral | Enalapril generichealth | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
15 Schedule 1 (table)
After:
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Blooms the Chemist Escitalopram | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
insert:
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
16 Schedule 1 (table)
Omit:
Ezetimibe | Tablet 10 mg | Oral | Blooms The Chemist Ezetimibe | between 1 July 2024 and 31 July 2024—0 months stock by reference to usual demand |
17 Schedule 1 (table)
Omit:
Fluorometholone | Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL | Application to the Eye | Flarex | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual PBS demand |
18 Schedule 1 (table)
After:
Furosemide | Oral solution 10 mg per mL, 30 mL | Oral | Lasix | 4 months stock by reference to usual PBS demand |
insert:
Gabapentin | Capsule 300 mg | Oral | Gabapentin generichealth | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
Gabapentin | Capsule 400 mg | Oral | Gabapentin generichealth | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
19 Schedule 1 (table)
Omit:
Ipratropium | Nebuliser solution containing ipratropium bromide 250 micrograms (as monohydrate) in 1 mL single dose units, 30 | Inhalation | Aeron 250 | between 1 June 2024 and 31 July 2024—0 months stock by reference to usual demand |
Ipratropium | Nebuliser solution containing ipratropium bromide 500 micrograms (as monohydrate) in 1 mL single dose units, 30 | Inhalation | Aeron 500 | between 1 June 2024 and 31 July 2024—0 months stock by reference to usual demand |
20 Schedule 1 (table)
After:
Lercanidipine | Tablet containing lercanidipine hydrochloride 20 mg | Oral | BTC Lercanidipine | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
insert:
Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral | APO-Levetiracetam | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral | Keppra | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral | Kerron | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral | Levetiracetam GH | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral | Levetiracetam-AFT | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Tablet 1 g | Oral | APO-Levetiracetam | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Tablet 1 g | Oral | Keppra | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Tablet 1 g | Oral | Kevtam 1000 | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Tablet 1 g | Oral | Levactam | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Tablet 1 g | Oral | Levetiracetam GH | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Tablet 1 g | Oral | Levetiracetam Mylan | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Tablet 1 g | Oral | Levetiracetam SZ | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Tablet 1 g | Oral | Levetiracetam Viatris | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Tablet 1 g | Oral | Levi 1000 | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Levetiracetam | Tablet 1 g | Oral | NOUMED LEVETIRACETAM | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand. |
Lisinopril | Tablet 20 mg | Oral | Lisinopril generichealth | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
21 Schedule 1 (table)
After:
Lithium | Tablet containing lithium carbonate 450 mg (slow release) | Oral | Quilonum SR | 6 months stock by reference to usual PBS demand |
insert:
Meloxicam | Tablet 15 mg | Oral | Pharmacor Meloxicam 15 | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
22 Schedule 1 (table)
After:
Meloxicam | Tablet 7.5 mg | Oral | MELOBIC | 4 months stock by reference to usual demand |
insert:
Meloxicam | Tablet 7.5 mg | Oral | Pharmacor Meloxicam 7.5 | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
23 Schedule 1 (table)
Omit:
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | Blooms the Chemist Metformin XR 1000 | between 1 July 2024 and 31 July 2024—0 months stock by reference to usual demand |
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Blooms the Chemist Metformin XR 500 | between 1 July 2024 and 31 July 2024—0 months stock by reference to usual demand |
24 Schedule 1 (table)
Omit:
Mitozantrone | Injection 25 mg (as hydrochloride) in 12.5 mL | Injection | Onkotrone | between 1 May 2024 and 30 July 2024—0 months stock by reference to usual demand |
25 Schedule 1 (table)
Omit:
Mycophenolic acid | Capsule containing mycophenolate mofetil 250 mg | Oral | CellCept | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |
Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | CellCept | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |
26 Schedule 1 (table)
Omit:
Pregabalin | Capsule 25 mg | Oral | Cipla Pregabalin | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |
Pregabalin | Capsule 300 mg | Oral | Cipla Pregabalin | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |
27 Schedule 1 (table)
Omit:
Pregabalin | Capsule 75 mg | Oral | Cipla Pregabalin | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |
28 Schedule 1 (table)
After:
Risperidone | Tablet 3 mg | Oral | Rispa | 3 months stock by reference to usual demand |
insert:
Rizatriptan | Tablet (orally disintegrating) 10 mg (as benzoate) | Oral | APO-Rizatriptan | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
Rizatriptan | Tablet (orally disintegrating) 10 mg (as benzoate) | Oral | Rizatriptan ODT GH | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
29 Schedule 1 (table)
After:
Temazepam | Tablet 10 mg | Oral | APO‑Temazepam | 2.5 months stock by reference to usual demand |
insert:
Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Viread | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
30 Schedule 1 (table)
After:
Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | Oral | Tenofovir Disoproxil Emtricitabine Viatris 300/200 | after 30 April 2024—4 months stock by reference to usual demand of both Tenofovir Disoproxil Emtricitabine Viatris 300/200 and Tenofovir Disoproxil Emtricitabine Mylan 300/200 added together |
insert:
Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg | Oral | Tenofovir EMT GH | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
31 Schedule 1 (table)
Omit:
Tobramycin | Injection 80 mg (as sulfate) in 2 mL (without preservative) | Injection | Pfizer Australia Pty Ltd | between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand |
substitute:
Tobramycin | Injection 80 mg (as sulfate) in 2 mL (without preservative) | Injection | Pfizer Australia Pty Ltd | 2 months stock by reference to usual demand |
32 Schedule 1 (table)
After:
Trimethoprim | Tablet 300 mg | Oral | Trimethoprim Viatris | after 30 April 2024—6 months stock by reference to usual demand of both Trimethoprim Viatris and Trimethoprim Mylan added together |
insert:
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valaciclovir generichealth | between 1 August 2024 and 31 October 2024—0 months stock by reference to usual demand |
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valacor 500 | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |
33 Schedule 1 (table)
Omit:
Valganciclovir | Tablet 450 mg (as hydrochloride) | Oral | VALGANCICLOVIR HETERO | between 1 June 2024 and 31 July 2024—0 months stock by reference to usual demand |
34 Schedule 1 (table)
After:
Voriconazole | Powder for oral suspension 40 mg per mL, 70 mL | Oral | Vfend | 4 months stock by reference to usual PBS demand |
insert:
Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Zoledronic Acid SUN | between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand |